• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.

作者信息

Sechet A, Hardy P, Hottelart C, Rasombololona M, Abighanem O, Oualim Z, Brazier M, Achard J M, Pruna A, Moriniere P, Fournier A

机构信息

Nephrology Unit, CHU Amiens, France.

出版信息

Artif Organs. 1998 Jul;22(7):564-8. doi: 10.1046/j.1525-1594.1998.06199.x.

DOI:10.1046/j.1525-1594.1998.06199.x
PMID:9684692
Abstract

A study has claimed that at an equal elemental calcium dose, CaCO3 was not less but equally as efficient in controlling predialysis hyperphosphatemia as calcium acetate, provided both calcium salts were ingested 5 min before meals instead of during meals because the higher acidity of the fasting gastric juice would allow for better dissociation of CaCO3. However, this study did not directly demonstrate that the efficiency of CaCO3 in controlling hyperphosphatemia was actually greater when it was administered before a meal than during a meal. To examine this point, we performed a 3 month randomized crossover trial in 12 reliable and stable patients maintained on chronic hemodialysis. Their plasma concentrations of calcium, protein, phosphate, bicarbonate, urea, and creatinine were measured before the first dialysis of each week and the amount of intact parathyroid hormone (PTH) at the beginning and at the end of each of the 3 months. Comparison of the plasma concentrations measured during the 2 modes of administration showed no significant differences in creatinine, urea, bicarbonate, or intact PTH. The mean (+/-SD) plasma concentration of PO4 was not significantly lower (1.88+/-0.50 vs. 1.74+/-0.41 mM) whereas the corrected level of plasma Ca was significantly lower (2.30+/-0.17 vs. 2.38+/-0.16 mM; p < 0.04) when CaCO3 was given before meals than during meals. In conclusion, the administration of CaCO3 before a meal does not increase its efficiency in controlling hyperphosphatemia because the level of plasma PO4 was actually slightly higher with this timing of administration whereas the comparison of the creatinine and urea levels suggested a stability of phosphate intake and the comparison of the PTH and bicarbonate levels suggested the stability of osteolysis and of the transcellular membrane shift of phosphate. Also, administration of CaCO3 before a meal is associated with significantly lower plasma corrected calcium, suggesting less absorption of calcium, which may be an advantage but only in hypercalcemic patients. There is no reason other than the prevention of its hypercalcemic effect to recommend the administration of CaCO3 just before meals rather than during meals.

摘要

相似文献

1
Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis.
Artif Organs. 1998 Jul;22(7):564-8. doi: 10.1046/j.1525-1594.1998.06199.x.
2
[Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].碳酸钙给药时间(进餐前或进餐期间)对维持性血液透析患者高磷血症控制的作用
Nephrologie. 1999;20(4):209-12.
3
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.奥美拉唑对胃酸分泌的抑制作用及碳酸钙对慢性血液透析患者高磷血症的控制效果。
Artif Organs. 1998 Jul;22(7):569-73. doi: 10.1046/j.1525-1594.1998.06200.x.
4
[Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis].[奥美拉唑对胃酸分泌的抑制作用及碳酸钙在维持性血液透析患者高磷血症控制中的疗效]
Nephrologie. 1999;20(4):213-6.
5
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
6
Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia.口服醋酸钙和碳酸钙对透析前高磷血症的控制。醋酸盐形式提供一半剂量的元素钙具有相当的疗效,且高钙血症发生率更低。
Nephron. 1992;60(1):6-11. doi: 10.1159/000186697.
7
Renal osteodystrophy in dialysis patients: diagnosis and treatment.透析患者的肾性骨营养不良:诊断与治疗
Artif Organs. 1998 Jul;22(7):530-57. doi: 10.1046/j.1525-1594.1998.06198.x.
8
Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
Nephron. 1989;52(2):125-32. doi: 10.1159/000185614.
9
[Comparison of calcium acetate and calcium carbonate for the control of predialysis hyperphosphatemia].
Nephrologie. 1991;12(4):193-7.
10
Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder.
Nephron. 1993;63(3):258-62. doi: 10.1159/000187207.

引用本文的文献

1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
2
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.
3
Safety of new phosphate binders for chronic renal failure.
新型磷酸盐结合剂用于慢性肾衰竭的安全性
Drug Saf. 2003;26(15):1093-115. doi: 10.2165/00002018-200326150-00003.